Daridorexant in treatment refractory cluster headache: A retrospective case series

OBJECTIVES/BACKGROUND: Cluster headache (CH) is one of the most excruciating pain conditions known in humans. Most patients experience nocturnal attacks, which further worsen sleep quality and overall quality of life. The management of CH includes acute and preventive treatments, and in some cases, transitional therapy with corticosteroids may be used to achieve pain freedom in a shorter time while giving preventive therapy. We report our preliminary experience with daridorexant, a selective dual orexin receptor antagonist approved for chronic insomnia, as an adjunctive treatment in patients with treatment refractory CH, nocturnal attacks, and bad quality of sleep. Our objective was to describe within-patient changes in nocturnal attack frequency, sleep quality, and headache-related disability before and after add-on daridorexant in refractory CH. METHODS: In this single-center, retrospective before-after case series, we reviewed clinical data from 10 patients followed at the Headache Center of the San Carlo Borromeo Hospital in Milan (Italy) between June 2023 and December 2024, with a diagnosis of either episodic or chronic CH, who experienced nocturnal attacks, sleep disturbances, and with inadequate response to standard treatments, including verapamil, lithium, or corticosteroids. In these patients, daridorexant was administered as add-on therapy, to treat the chronic insomnia. The frequency and features of CH attacks, sleep quality, headache-related disability, and quality-of-life evaluations were assessed before and after treatment. RESULTS: Treatment with daridorexant was associated with a significant reduction in nocturnal attacks, from 13.1 ± 7.5 to 6.4 ± 7.7 attacks per week (p < 0.050; n = 10/10). Patients also reported improved quality of life, with mean subjective quality-of-life scores increasing from 37% ± 15.6% to 61% ± 20.4% (p = 0.001; n = 10/10). Headache-related impact was reduced, with mean Headache Impact Test 6 scores decreasing from 62.0 ± 7.4 to 48.8 ± 16.2 (p < 0.050; n = 10/10). In addition, no patient reported worsening on the Patient Global Impression of Change scale, and eight of the nine out of 10 available Patient Global Impression of Change ratings indicated improvement. Daridorexant was generally well-tolerated, with adverse events reported in three out of 10 patients (30%), leading to treatment discontinuation in one patient. CONCLUSION: Daridorexant was significantly associated particularly with a reduction in the number of nocturnal attacks in patients with CH refractory to conventional therapies. These pilot preliminary results suggest a potential role for daridorexant as an adjunctive option for patients with CH, particularly those with a poor response to traditional therapies, nocturnal attacks, and sleep disturbances. Further prospective, controlled studies are warranted to confirm these findings and clarify the mechanisms underlying the observed clinical benefits.

Authors

Institutions

Publication Details

Journal
Headache The Journal of Head and Face Pain
Published
2026-11-16
DOI
https://doi.org/10.1111/head.70196
Primary Topic
Migraine and Headache Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Daridorexant in treatment refractory cluster headache: A retrospective case series

Alberto Galli, Micaela Robotti, Giacomo Querzola, Fabio Frediani et al.
1 links
Headache The Journal of Head and Face Pain
Migraine and Headache Studies
article

Daridorexant in treatment refractory cluster headache: A retrospective case series

Alberto Galli, Micaela Robotti, Giacomo Querzola, Fabio Frediani, Riccardo Altavilla, Michela Anna Maria Mauri
article en

Abstract

OBJECTIVES/BACKGROUND: Cluster headache (CH) is one of the most excruciating pain conditions known in humans. Most patients experience nocturnal attacks, which further worsen sleep quality and overall quality of life. The management of CH includes acute and preventive treatments, and in some cases, transitional therapy with corticosteroids may be used to achieve pain freedom in a shorter time while giving preventive therapy. We report our preliminary experience with daridorexant, a selective dual orexin receptor antagonist approved for chronic insomnia, as an adjunctive treatment in patients with treatment refractory CH, nocturnal attacks, and bad quality of sleep. Our objective was to describe within-patient changes in nocturnal attack frequency, sleep quality, and headache-related disability before and after add-on daridorexant in refractory CH. METHODS: In this single-center, retrospective before-after case series, we reviewed clinical data from 10 patients followed at the Headache Center of the San Carlo Borromeo Hospital in Milan (Italy) between June 2023 and December 2024, with a diagnosis of either episodic or chronic CH, who experienced nocturnal attacks, sleep disturbances, and with inadequate response to standard treatments, including verapamil, lithium, or corticosteroids. In these patients, daridorexant was administered as add-on therapy, to treat the chronic insomnia. The frequency and features of CH attacks, sleep quality, headache-related disability, and quality-of-life evaluations were assessed before and after treatment. RESULTS: Treatment with daridorexant was associated with a significant reduction in nocturnal attacks, from 13.1 ± 7.5 to 6.4 ± 7.7 attacks per week (p < 0.050; n = 10/10). Patients also reported improved quality of life, with mean subjective quality-of-life scores increasing from 37% ± 15.6% to 61% ± 20.4% (p = 0.001; n = 10/10). Headache-related impact was reduced, with mean Headache Impact Test 6 scores decreasing from 62.0 ± 7.4 to 48.8 ± 16.2 (p < 0.050; n = 10/10). In addition, no patient reported worsening on the Patient Global Impression of Change scale, and eight of the nine out of 10 available Patient Global Impression of Change ratings indicated improvement. Daridorexant was generally well-tolerated, with adverse events reported in three out of 10 patients (30%), leading to treatment discontinuation in one patient. CONCLUSION: Daridorexant was significantly associated particularly with a reduction in the number of nocturnal attacks in patients with CH refractory to conventional therapies. These pilot preliminary results suggest a potential role for daridorexant as an adjunctive option for patients with CH, particularly those with a poor response to traditional therapies, nocturnal attacks, and sleep disturbances. Further prospective, controlled studies are warranted to confirm these findings and clarify the mechanisms underlying the observed clinical benefits.

Headache The Journal of Head and Face Pain
Ospedale San Carlo (IT), Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo (IT)
Good health and well-being
Migraine and Headache Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon